Bellicum Pharmaceuticals, Inc. (BLCM) financial statements (2020 and earlier)

Company profile

Business Address 2130 WEST HOLCOMBE BOULEVARD
HOUSTON, TX 77030
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9193393370
Cash and cash equivalents9144393370
Short-term investments 49   
Restricted cash and investments3    
Assets held-for-sale, not part of disposal group17    
Other undisclosed current assets12637227
Total current assets:1129510210697
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment32126177
Long-term investments and receivables  1 56
Long-term investments  1 56
Restricted cash and investments 5610 
Other noncurrent assets10000
Total noncurrent assets:426342664
TOTAL ASSETS:116122136132160
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:101210137
Accounts payable 4342
Accrued liabilities 9695
Employee-related liabilities2    
Other undisclosed accounts payable and accrued liabilities8    
Debt110020
Deferred rent credit 0
Derivative instruments and hedges, liabilities52    
Deferred revenue and credits200
Contract with customer, liability3
Other undisclosed current liabilities21    
Total current liabilities:941612157
Noncurrent Liabilities
Long-term debt and lease obligation26363500
Long-term debt, excluding current maturities263635  
Capital lease obligations0000
Liabilities, other than long-term debt 1421
Deferred revenue and credits421
Deferred rent credit 1
Other undisclosed noncurrent liabilities1  18 
Total noncurrent liabilities:273739201
Total liabilities:1215351358
Temporary equity, carrying amount21    
Stockholders' equity
Stockholders' equity attributable to parent(26)688597152
Common stock10000
Treasury stock, value(5)(5)(5)(5)(5)
Additional paid in capital512494412332319
Accumulated other comprehensive income (loss)(0)(0)(0)0(0)
Accumulated deficit(533)(421)(323)(231)(161)
Total stockholders' equity:(26)688597152
TOTAL LIABILITIES AND EQUITY:116122136132160

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues72000
Revenue, net000
Net investment income12   
Cost of revenue
(Cost of Goods and Services Sold)
 (0) (1)(3)
Gross profit:710(0)(3)
Operating expenses(95)(97)(88)(69)(49)
Other undisclosed operating income (loss) (0) 13
Operating loss:(87)(95)(87)(68)(49)
Nonoperating income (expense)(25)(3)(4)(1)1
Interest and debt expense(4)(4)(2)(2)(0)
Net loss:(117)(102)(94)(71)(49)
Other undisclosed net income attributable to parent44220
Net loss available to common stockholders, diluted:(112)(98)(92)(69)(49)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(117)(102)(94)(71)(49)
Other comprehensive loss(113)(98)(92)(69)(49)
Comprehensive loss:(229)(200)(185)(140)(97)
Other undisclosed comprehensive income, net of tax, attributable to parent117102947149
Comprehensive loss, net of tax, attributable to parent:(113)(98)(92)(69)(49)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: